Short Description Tornado Tx co‑founder translating selective TORC1 inhibitors.
Description Dr. Joan Mannick formerly ran Novartis’ exploratory clinical program that showed low‑dose rapalogs enhance vaccine response in the elderly. She co‑founded resTORbio and, more recently, Tornado Therapeutics to develop TORC1‑specific inhibitors with improved safety. Her Phase 2 data in respiratory infections provided the first human proof that targeting aging pathways can confer multi‑system benefits. Mannick sits on the FDA’s Geroscience Working Group and mentors female founders in biotech.